A visual inspection of the funnel plots for the meta-analysis assessing the association between SGLT2 inhibitor use and the risk of CTRCD in patients with cancer showed symmetry, suggesting a low likelihood of publication bias (Figure 6). Here, SLC5A2 is linked to cancer.